FCGR2B
Low affinity immunoglobulin gamma Fc region receptor II-b
Also known as: CD32, CD32B, FCG2, FCG2B_HUMAN, FcgammaRIIb, FCGR2, FcGRIIB
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P31994
- Gene
- FCGR2B
- Ensembl
- ENSG00000072694
- Chromosome
- 1
- Canonical length
- 310 aa
- Protein class
- Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted membrane proteins
OverviewNCBI Gene
The protein encoded by this gene is a low affinity receptor for the Fc region of immunoglobulin gamma complexes. The encoded protein is involved in the phagocytosis of immune complexes and in the regulation of antibody production by B-cells. Variations in this gene may increase susceptibilty to systemic lupus erythematosus (SLE). Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jun 2010]
Canonical amino-acid sequenceUniProt
310 residues, UniProt reviewed canonical sequence.
>P31994|FCGR2B
1 MGILSFLPVL ATESDWADCK SPQPWGHMLL WTAVLFLAPV AGTPAAPPKA VLKLEPQWIN
61 VLQEDSVTLT CRGTHSPESD SIQWFHNGNL IPTHTQPSYR FKANNNDSGE YTCQTGQTSL
121 SDPVHLTVLS EWLVLQTPHL EFQEGETIVL RCHSWKDKPL VKVTFFQNGK SKKFSRSDPN
181 FSIPQANHSH SGDYHCTGNI GYTLYSSKPV TITVQAPSSS PMGIIVAVVT GIAVAAIVAA
241 VVALIYCRKK RISALPGYPE CREMGETLPE KPANPTNPDE ADKVGAENTI TYSLLMHPDA
301 LEEPDDQNRILocalizationUniProt · AlphaFold · HPA
Whether an antibody against FCGR2B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.45
- Highest tissue expression
- 378 nTPM
Expression across tissuesHPA
Tissue
- placenta: 378 nTPM
- liver: 40 nTPM
- adipose tissue: 29 nTPM
- tonsil: 28 nTPM
- spleen: 25 nTPM
- lung: 21 nTPM
Single-cell type
- cdc: 237 nCPM
- macrophages: 117 nCPM
- plasma cells: 72 nCPM
- b-cells: 56 nCPM
- vascular endothelial cells: 49 nCPM
- monocytes: 40 nCPM
Immune cell
- basophil: 329 nTPM
- memory B-cell: 204 nTPM
- naive B-cell: 161 nTPM
- myeloid DC: 73 nTPM
- neutrophil: 54 nTPM
- eosinophil: 27 nTPM
Brain region
- white matter: 12 nTPM
- medulla oblongata: 9.1 nTPM
- choroid plexus: 8.5 nTPM
- spinal cord: 4.2 nTPM
- pons: 3.1 nTPM
- thalamus: 2.6 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FCGR2B.
Disease | AllUniProt
Conditions FCGR2B is implicated in, by any mechanism.
- Systemic lupus erythematosus (SLE) MIM:152700
Disease | AutoantibodyPubMed
Conditions in which antibodies against FCGR2B are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for FCGR2B from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Vaccine-Induced Anti-IgE Antibodies Neutralize Free IgE but Fail to Bind and Activate Mast Cell-Displayed IgE.
2025 · Allergy · RCR 2.4 · 7 citations - FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus.
1999 · Eur Cytokine Netw · RCR 0.9 · 49 citations - Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice.
2007 · Eur J Immunol · RCR 0.7 · 35 citations - Suppression of dsDNA-specific B lymphocytes reduces disease symptoms in SCID model of mouse lupus.
2014 · Autoimmunity · RCR 0.2 · 5 citations - Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.
2012 · Hum Gene Ther Methods · RCR 0.2 · 5 citations
Show 1 more
- Suppression of Disease-Associated B Lymphocytes by GAD65 Epitope-Carrying Protein-Engineered Molecules in a Streptozotocin-Induced Mouse Model of Diabetes.
2019 · Monoclon Antib Immunodiagn Immunother · RCR 0.1 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.63
- gnomAD pLI
- 0.46
- gnomAD missense Z
- 0.11
- DepMap mean gene effect
- -0.21
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- antibody-dependent cellular cytotoxicity
- antigen processing and presentation of exogenous peptide antigen via MHC class II
- cell surface receptor signaling pathway
- cellular response to amyloid-beta
- cellular response to molecule of bacterial origin
- cerebellum development
- defense response
- Fc-gamma receptor signaling pathway
- follicular B cell differentiation
- immunoglobulin mediated immune response
- inflammatory response
- mature B cell differentiation involved in immune response
- negative regulation of acute inflammatory response to antigenic stimulus
- negative regulation of B cell activation
- negative regulation of B cell proliferation
- negative regulation of B cell receptor signaling pathway
- negative regulation of cytokine production
- negative regulation of cytotoxic T cell degranulation
- negative regulation of dendritic cell antigen processing and presentation
- negative regulation of dendritic cell differentiation
- negative regulation of humoral immune response mediated by circulating immunoglobulin
- negative regulation of immune response
- negative regulation of immunoglobulin production
- negative regulation of interleukin-10 production
- negative regulation of macrophage activation
- negative regulation of neutrophil activation
- negative regulation of phagocytosis
- phagocytosis
- phagocytosis, engulfment
- positive regulation of humoral immune response
- positive regulation of JNK cascade
- positive regulation of phagocytosis
- positive regulation of response to endoplasmic reticulum stress
- positive regulation of tumor necrosis factor production
- receptor-mediated endocytosis
- regulation of adaptive immune response
- regulation of dendritic spine maintenance
- regulation of innate immune response
- response to bacterium
- follicular dendritic cell activation
- immune complex clearance by monocytes and macrophages
- immune effector process
- negative regulation of antibody-dependent cellular cytotoxicity
- negative regulation of type I hypersensitivity
- regulation of B cell antigen processing and presentation
- regulation of endoplasmic reticulum stress-induced neuron intrinsic apoptotic signaling pathway
- regulation of immune complex clearance by monocytes and macrophages
Molecular functions
- amyloid-beta binding
- IgG binding
- IgG receptor activity
- low-affinity IgG receptor activity
- protein-containing complex binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of FCGR2B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FCGR2B as an antibody target. Whether an autoantibody or antibody against FCGR2B could matter depends on whether native FCGR2B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FCGR2B is annotated at the cell surface, where native FCGR2B is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Source-annotated serology context
The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.
- The encoded protein is involved in the phagocytosis of immune complexes and in the regulation of antibody production by B-cells.
Loading the interactive Seroatlas protein explorer...